Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Brain Tumor Therapy Devices Market $1.8 Billion by 2031

The global market for brain tumor therapy devices predicted to reach $1.8 billion by 2031, expanding at a double-digit CAGR of 13.1% over the forecast period, driven by increasing incidence of brain cancer in developed countries, availability of minimally invasive surgical procedures, and recent technological advances.

  • The most important risk factors for brain cancer include family history, hormones, immune deficiency, nutrition, alcohol consumption, cigarette and aspartame, radiation, and cell phone use.
    • Despite decades of research, brain tumors remain among the deadliest of all forms of cancer. The ability of these tumors to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. 
Global Brain Tumor Therapy Devices Market

The nervous system tumors are a kind of neoplasms, which form several morphological subgroups with different behavior patterns. Brain cancer is the 10th leading cause of death for men and women. The annual global age-standardized incidence of primary malignant brain tumors is ~3.7 per 100,000 for males and 2.6 per 100,000 for females.

  • The incidence rates appear to be higher more developed countries than in less developed countries. The incidence of brain tumors in the last 20 years is increasing in all ages; however, it has grown more than 40% percent in adult person.
    • Males also generally have higher rates of primary malignant brain tumors while females have higher rates of non-malignant tumors, primarily meningiomas.
      • Data from several national cancer registries support differences in the epidemiology of brain tumors in children versus adults.

A major priority based on available evidence and technologies includes expanding research in genetics and molecular epidemiology of brain tumors. The Brain Tumor Epidemiology Consortium (BTEC) has taken an active role in promoting understudied groups such as pediatric brain tumors, the etiology of rare glioma subtypes, such as oligodendroglioma, and meningioma, which not uncommon, has only recently been systematically registered in the US. The glioblastomas multiforme (GBM), the most common primary brain cancer of glial origin, are almost universally fatal within 2 years of diagnosis despite maximal surgical and medical therapy.

Treatments for different brain tumors will depend on symptoms, location and biological aggressiveness of the tumor, the extent of possible surgical resection, and the tumor tissue pathology characteristics. Treatment options include surgery, radiation therapy, chemotherapy, targeted biological agents, or a combination of these. In the past two decades, researchers have developed new techniques of delivering radiation that target the brain tumor while protecting nearby healthy tissues.

  • These radiation treatments include intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), three-dimensional conformal radiation therapy (3D-CRT), brachytherapy, proton therapy, and stereotactic radiosurgery.
    • The IMRT is an advanced mode of high-precision radiotherapy that utilizes computer-controlled x-ray accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
    • The SRS is a highly precise form of radiation therapy that directs narrow beams of radiation to the tumor from different angles.
    • The 3D-CRT is a conventional form of radiation treatment delivery that uses a specific arrangement of x-ray beams designed to conform to the shape of the tumor to maximize tumor dose and minimize normal surrounding tissue dose. Brachytherapy is the temporary placement of radioactive source(s) within the body, usually employed to give an extra dose or boost of radiation to the area of the excision site or to any residual tumor.
    • Proton therapy is a type of external-beam radiation therapy that uses protons rather than x-rays. At high energy, protons can destroy tumor cells. Proton beam therapy is typically used for tumors when less radiation is needed because of the location.
    • Stereotactic radiosurgery. Stereotactic radiosurgery is the use of a single, high dose of radiation given directly to the tumor and not healthy tissue. It works best for a tumor that is only in 1 area of the brain and certain noncancerous tumors.

The global market for brain cancer (neoplasms) therapy devices research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for brain tumor treatment devices segmented by product [directed energy-based therapy devices / thermal ablation catheter and devices (microwave ablation catheters and devices, radiofrequency ablation catheters and devices, cryoablation catheters and devices, ultrasound ablation catheters and devices, laser ablation devices), drug/fluid delivery and infusion therapy devices/ energy-based drug delivery (electroporation devices)], and geography.

  • Ablative therapies have been used for the treatment of neurological disorders for many years. They have been used both for creating therapeutic lesions within dysfunctional brain circuits and to destroy intracranial tumors and space-occupying masses.
    • Despite the introduction of new effective drugs and neuromodulation techniques, which became more popular and subsequently caused brain ablation techniques to fall out favor, recent technological advances have led to the resurgence of lesioning with an improved safety profile.
      • Currently, the four main ablative techniques that are used for ablative brain surgery are radiofrequency thermo-ablation, stereotactic radiosurgery, laser interstitial thermal therapy and magnetic resonance-guided focused ultrasound thermal ablation.
  • Based on the products, the microwave ablation catheters and devices segment accounted for the largest share of the total market, whereas the laser ablation devices segment anticipated to witness the fastest double-digit growth rate in the coming years. The electroporation drug delivery devices segment also expected to grow at the fastest double-digit growth rate in the near future. 
  • In the recent years, the high-intensity focused ultrasound (HIFU) is being explored as an alternative treatment to resection, chemotherapy, and radiotherapy. The ultrasound ablation catheters and devices segment expected to outgrow the microwave ablation catheters and devices segment by the end of forecast period.
  • Interstitial HIFU therapy for intracranial tumors utilizes ultrasound technology as a minimally invasive method of tumor ablation.
    • The application of an automated system via a robot improves workflow and efficiency of the delivery system. The MR-guided focused ultrasound (MRgFUS) is a novel, noninvasive technique used for thermal ablation.
      • At the same time, MRI-guidance and MR-thermography allow for accurate targeting and real-time monitoring of energy deposition.
  • The laser interstitial thermal therapy (LITT) is a novel minimally invasive neurosurgical procedure used as a primary or adjuvant treatment for glioblastoma through a stereotactically positioned probe to an intracranial lesion for controlled thermal ablation of the pathological tissue.
    • For example, the NeuroBlate laser ablation system (Monteris Medical, Inc.) and the Visualase Thermal Therapy System (Medtronic plc.) received US FDA approval in 2007 and 2009, respectively.
      • These commercial LITT platforms use MR thermometry software that allows the surgeon to define a maximum temperature threshold at the periphery of the target lesion; surpassing this threshold automatically triggers laser shutdown to protect off-target regions.
        • The Visualase and NeuroBlate LITT systems also improved procedure safety in designing a cooling sheath to surround the laser fiber along the length of laser probe, thereby limiting thermal damage to the tip of the probe.

The recent development of techniques that allow for precise targeting, accurate delivery of thermal doses and real-time visualization of induced tissue damage during the procedure have resulted in novel techniques for cerebral ablation such as magnetic resonance-guided focused ultrasound or laser interstitial thermal therapy. However, older techniques such as radiofrequency thermal ablation or stereotactic radiosurgery still have a pivotal role in the management of a variety of neurological disorders.

The global market for brain tumor therapy devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the developed countries in North America and Europe region as well as Japan in Asia Pacific region estimated to register the fastest growth rate accounting for the largest share of the total market.
    • Globally, large variability in the magnitude of the diagnosis of new cases of brain cancer was found, with a 5-fold difference between the highest rates (mainly in Europe) and the lowest (mainly in Asia).
      • Previous reports demonstrated that the incidence of brain tumor is different among countries worldwide. In general, the incidence of Brain tumor is higher in the West than the East and it is also higher in the developed countries than in developing countries.
        • The age-standardized distribution of these diseases is also different worldwide, with the highest incidence in Australia, North America, and North Europe and the lowest incidence in Africa.

In addition, the global market for brain tumor therapy devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global market for brain cancer treatment devices and profiled in this report include Accuray, Inc., BrainLAB AG, CarThera SAS, Elekta AB, GT Medical Technologies, Inc., iCAD, Inc., Integra LifeSciences Holdings Corporation, MagForce AG, Medtronic plc, MedWaves, Inc., Monteris Medical, Inc., Novocure GmbH, Siemens Healthineers AG (Varian Medical Systems, Inc.), and Thermo Fisher Scientific, Inc.

  • Product
    • Directed Energy-based Therapy Devices
      • Thermal Ablation Catheter and Devices
        • Microwave Ablation Catheters and Devices
        • Radiofrequency Ablation Catheters and Devices
        • Cryoablation Catheters and Devices
        • Ultrasound Ablation Catheters and Devices
        • Laser Ablation Devices
    • Drug/Fluid Delivery and Infusion Therapy Devices
      • Energy-based Drug Delivery
        • Electroporation Devices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Accuray, Inc.
    • BrainLAB AG
    • CarThera SAS
    • Elekta AB
    • GT Medical Technologies, Inc.
    • iCAD, Inc.
    • Integra LifeSciences Holdings Corporation
    • MagForce AG
    • Medtronic plc
    • MedWaves, Inc.
    • Monteris Medical, Inc.
    • Novocure GmbH
    • Siemens Healthineers AG (Varian Medical Systems, Inc.)
    • Thermo Fisher Scientific, Inc.

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/brain-cancer-neoplasms-treatment-devices-market/ 

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com